Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 8, Issue 2 (2019)

Genetic polymorphisms of Hiv-1 resistance-conferring polymorphisms (Sdf1-3′A, Ccr2-64i and Ccr5-Δ32) in Population of Madhya Pradesh

Author(s):
Hiya Jain, Mohd Shahab and Deepak Bharti
Abstract:
The Human Immunodeficiency Virus (HIV) which cause Acquired Immune Deficiency Syndrome (AIDS) in Human. Among retroviruses, human immune deficiency virus (HIV) remains major global health issue; it infects millions of people worldwide annually. A total of 50 blood samples were collected and after blood sample collection, DNA was extracted. Extracted DNA samples were used for the Genetic assessment of selected genes of Chemokine Receptors (Chemokine Receptor 5 and Chemokine Receptor 2) and one ligand (SDF1). SDF1 is a ligand of CXCR4 receptor. For the polymorphism study selected primers were used for PCR of Chemokine Receptor 5, Chemokine Receptor2 and Stromal derived factor 1. Amplified PCR products were subjected to Restriction digestion using established protocols, Finally RFLP data of Chemokine Receptor 5, Chemokine Receptor 2 and Stromal derived factor 1, were further validated using random samples by DNA sequencing. Progression rate of HIV-1 virus after infection in slower in those individuals who carry the mutant form of genes such as CCR5, CCR2 and SDF1. These mutations have originated outside of India, Therefore the frequency of minor alleles for studied genes were reported very less (CCR5 = 0,CCR2=0.08, SDF1=0.16) in the present investigation. The present study concludes that if caste population will get infecting from the virus, the infection will be severe with rapid replication in caste population of Indian State M.P.
Pages: 333-336  |  470 Views  69 Downloads


The Pharma Innovation Journal
How to cite this article:
Hiya Jain, Mohd Shahab, Deepak Bharti. Genetic polymorphisms of Hiv-1 resistance-conferring polymorphisms (Sdf1-3′A, Ccr2-64i and Ccr5-Δ32) in Population of Madhya Pradesh. Pharma Innovation 2019;8(2):333-336.

Call for book chapter